Cardinal Health (CAH) Stock Looks Fully Priced On Its 403% Run
Cardinal Health stock has delivered a very strong 5 year return, yet the current valuation checks lean expensive rather than cheap, which raises the question of how much optimism is already in the price.
- Cardinal Health has returned about 403.0% over 5 years, which puts recent gains front and center for anyone thinking about new money going into the stock.
- The acquisitions of Strive Medical and AdaptHealth’s diabetes business may support growth in at home care and earnings, while integration execution and regulatory complexity can still weigh on how much investors are willing to pay for that story.
- With the company scoring only 2 out of 6 on broader valuation checks, Cardinal Health currently screens as not a clear bargain on traditional metrics.
The issue now is whether Cardinal Health's recent acquisition driven momentum and strong long term return justify the current pricing, or whether expectations have moved ahead of fundamentals.
Is Cardinal Health Getting Expensive on Earnings?
P/E is usually a reasonable yardstick for Cardinal Health because earnings remain a key focus for investors in large, established healthcare distributors. On this measure, Cardinal Health trades at about 34.6x earnings, which is well above the broader healthcare industry average of roughly 25.0x and also ahead of the peer group average near 25.9x. That puts a clear premium on the stock compared with many similar companies.
The fair P/E multiple for Cardinal Health, based on its risk profile, margins and sector, is estimated at around 29.2x. The current 34.6x level sits meaningfully above that reference point, which suggests investors are already paying up for the at home care push and earnings guidance moves following the Strive Medical and AdaptHealth deals. On this framework, the market is building in a healthy amount of optimism about Cardinal Health’s profit outlook.
On the P/E multiple alone, Cardinal Health stock currently looks overvalued relative to both tailored fair value estimates and sector peers.
See what the numbers say about this price — find out in our valuation breakdown.
The Cardinal Health Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Cardinal Health pick up where the P/E discussion leaves off and set out the specific growth, margin and earnings paths that would need to play out for Cardinal Health's stock to be worth meaningfully more or less than it is today, using clear scenarios on the Community page. Instead of relying on a single ratio or model output, they unpack the future conditions that figure relies on so you can watch how those assumptions hold up over time.
You can add your own narrative on Cardinal Health and build a clear, number-driven case on whether moves such as the Strive Medical and AdaptHealth diabetes acquisitions are aligned with today's valuation. Share your view in the Simply Wall St community and see how your thesis holds up as new results and guidance arrive.
Do you think there's more to the story for Cardinal Health? Head over to our Community to see what others are saying!
The Bottom Line
For Cardinal Health, the current market multiple points to an overvalued stock where investors already pay a premium for the at home care story and recent earnings momentum. The broader valuation checks also sit on the weaker side, which reinforces the idea that there is limited room for disappointment at today’s pricing. The key question from here is whether Cardinal Health can deliver on execution of the Strive Medical and AdaptHealth integrations and sustain enough earnings strength to keep investors comfortable with that higher P/E.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com